Analysis
Is compounded semaglutide FDA-approved?
No. Learn how compounded semaglutide differs from an approved drug, what pharmacy licensing means, and how to check the claims in a telehealth offer.
Claims are checked against the sources cited in this article. Nothing here is individualized medical advice. How we research
On this page
No. Compounded semaglutide is not FDA-approved, even when a prescription is issued and a licensed pharmacy prepares it. The approval of a branded semaglutide medicine does not extend to a separately compounded prescription. FDA approval, pharmacy licensing and permission to compound are different questions.
Sources checked October 9, 2026. This guide explains regulatory labels and purchasing information, not whether a particular medicine is appropriate for you.
What does “not FDA-approved” actually mean?
FDA says it does not review compounded medicines for safety, effectiveness or quality before they are marketed. This is a statement about the review process, not a clinical verdict about your particular prescription. A consultation, prescription or pharmacy license does not replace that product-review process. FDA compounding questions and answers
The practical distinction is between a drug product and an ingredient name. “Semaglutide” on a website tells you what the seller says the prescription contains. It does not identify an approved manufacturer, an approved finished product or the specific terms under which a pharmacy prepared the medicine. Those details require separate answers.
Before comparing an offer, write down the exact product description. Is the advertised price for a branded medicine, a compounded injection, a compounded pill or the consultation alone? A page that discusses Ozempic or Wegovy and then sells a different product can leave that question unclear. Our semaglutide guide provides a starting point for identifying the offering; the actual prescription and pharmacy documentation matter more than an advertising headline.
Is it an approved generic of Ozempic or Wegovy?
No. FDA distinguishes compounded drugs from generics approved through the agency’s generic-drug pathway. Calling a compounded prescription “generic Ozempic” does not give it an approved generic’s status. The seller should identify it as compounded rather than letting a familiar brand name stand in for its product identity. FDA’s explanation of compounded versus generic drugs
That distinction also matters when comparing prices. A quote for a compounded prescription and a manufacturer offer for a branded product are not quotes for the same approved product. You can compare the payments and service commitments, but a cost table should not imply regulatory equivalence.
For example, our compounded semaglutide price comparison covers the reviewed compounded offers described in that table. It is not a list of approved Ozempic or Wegovy generics. Read the formulation, included services and payment terms alongside the amount, rather than treating every semaglutide headline as interchangeable.
The table’s covered injection providers are Gentle Health, OrderlyMeds, Mochi Health and Henry Meds. Their listings identify published offers, not FDA-approved compounded products. Gentle’s own homepage also states that its compounded medicines are not FDA-approved; use the same product-identity test for every seller.
What about semaglutide sodium or semaglutide acetate?
FDA specifically identifies semaglutide sodium and semaglutide acetate as different active ingredients from those used in approved drugs. The agency says it is unaware of a lawful basis for using those salt forms in compounding. A seller’s use of the broader word “semaglutide” does not resolve which ingredient it actually supplies. FDA’s concerns about unapproved GLP-1 drugs
Ask for the exact ingredient name, not simply confirmation that a product is “a GLP-1.” If the website and prescription paperwork use different descriptions, ask the prescriber and dispensing pharmacy to explain the discrepancy before relying on a comparison. This is a product-identification check, not a way to determine a medicine’s suitability yourself.
The same applies to a product advertised as semaglutide with B12. An additional ingredient is a formulation detail; it does not create FDA approval. Nor does the word “personalized” identify the legal basis for a particular prescription. FDA’s April 1, 2026 clarification discusses circumstances in which semaglutide combined with B12 can still be considered essentially a copy of commercially available products. FDA’s compounding-policy clarification
Did the shortage make compounded semaglutide approved?
No. Shortage-related compounding policies concerned the conditions for compounding, not approval of the compounded products. FDA determined that the semaglutide injection shortage was resolved on February 21, 2025. Its later updates describe the end of the temporary enforcement periods tied to that shortage. FDA’s shortage and transition updates
This explains why an older article about shortage access can be misleading when used to assess a current offer. Check the date and what it actually says. A historical allowance connected to a shortage is not a permanent approval, and a local pharmacy being out of stock is not itself a new national shortage determination.
There is also no single yes-or-no seller check that substitutes for all applicable compounding conditions. A prescription-specific exception, the pharmacy’s category and state requirements concern lawful compounding. None of those makes the finished compounded product FDA-approved.
Does “FDA-registered pharmacy” mean an approved product?
No. A facility’s registration is a different type of record from a drug’s approval. FDA’s outsourcing-facility register provides facility information, including inspection and action columns. Some listed facilities have not yet been inspected. Read the record as a facility record, not an approval stamp for every prescription it supplies. FDA registered outsourcing facilities
Similarly, a state pharmacy license concerns the pharmacy. Start by requesting the dispensing and compounding pharmacy names, addresses and contact information, then use the relevant state board’s database. FDA provides a directory of state pharmacy boards. A telehealth brand and the pharmacy preparing the medicine may be different organizations.
What should an offer explain clearly?
A useful offer should let you distinguish the product from the service selling it. Ask these practical questions:
- Is this an FDA-approved branded product or a compounded prescription?
- What exact ingredient and formulation will the prescription identify?
- Which pharmacy prepares it, and which pharmacy dispenses it?
- What does the quoted payment include: medicine, consultation, shipping and required membership?
- What commitment applies, and what happens to future charges if you cancel?
An unanswered question is a reason to request clarification, not proof that the product is approved or that the seller violates a particular rule. Keep the offer and written answers together so the comparison reflects the product actually being sold.
The bottom line is straightforward: compounded semaglutide is not FDA-approved. You can still investigate a pharmacy’s identity, its licensing and the prescription’s legal framework, but those checks answer different questions. For pricing, use our all-in compounded GLP-1 comparison; for finding companies, use the provider directory. Neither directory placement nor a favorable price changes the product’s approval status.